Not really related, but I wanted to mention this, since some people really want to show Novartis as evil, and while they probably charge too much for their drugs in the US, their medicine actually saves lives, my dad being the best example of that.
Why Chemotherapy That Costs $70,000 in the U.S. Costs $2,500 in India
11–20 of 176 posts
Re: Why Chemotherapy That Costs $70,000 in the U.S. Costs $2,500 in India
#12> the patentability of modifications to existing drugs under Indian law A key point here is that the original drug itself was patented, and has expired. The issue that the Indian court had with Gleevec patent application is that it only rearranged the molecule in a new crystal pattern, ie Polymorphism. The Indian court consider polymorphism to be a well known technique when working with drugs, and just applying polym…
Re: Why Chemotherapy That Costs $70,000 in the U.S. Costs $2,500 in India
#13This is basically the paradox of US healthcare innovation. Canada can tell its pharmaceutical companies, "yeah, that cool drug you just invented, we're not gonna pay you what you want for that." And what option does the pharmaceutical company have? Convince healthcare providers to charge retail prices to their patients as an out-of-pocket expense, or... reduce prices accordingly. Because healthcare payments are not f…
US firms are investing less in R&D relatively to their rank http://en.wikipedia.org/wiki/Pharmaceutical_industry#Market_... than their French/UK (publicly-funded healthcare) counterparts. The US are not "subsidizing it for poor countries" more than other rich countries. The truth in the case you're making is not specific to healthcare and is that "research (private and public) of rich countries that can afford it" be…
Re: Why Chemotherapy That Costs $70,000 in the U.S. Costs $2,500 in India
#14This is basically the paradox of US healthcare innovation. Canada can tell its pharmaceutical companies, "yeah, that cool drug you just invented, we're not gonna pay you what you want for that." And what option does the pharmaceutical company have? Convince healthcare providers to charge retail prices to their patients as an out-of-pocket expense, or... reduce prices accordingly. Because healthcare payments are not f…
US firms are investing less in R&D relatively to their rank http://en.wikipedia.org/wiki/Pharmaceutical_industry#Market_... than their French/UK (publicly-funded healthcare) counterparts. The US are not "subsidizing it for poor countries" more than other rich countries. The truth in the case you're making is not specific to healthcare and is that "research (private and public) of rich countries that can afford it" be…
Re: Why Chemotherapy That Costs $70,000 in the U.S. Costs $2,500 in India
#15Earlier quoted context omitted.
US firms are investing less in R&D relatively to their rank http://en.wikipedia.org/wiki/Pharmaceutical_industry#Market_... than their French/UK (publicly-funded healthcare) counterparts. The US are not "subsidizing it for poor countries" more than other rich countries. The truth in the case you're making is not specific to healthcare and is that "research (private and public) of rich countries that can afford it" be…
From that list 48.17% of all health care R&D spend is by US based companies. Sounds like the US is subsidizing the world to me.
Re: Why Chemotherapy That Costs $70,000 in the U.S. Costs $2,500 in India
#16My father has been on Glivec for the last 7 years, and this is the only reason he is still alive - when he was diagnosed with GIST doctors told him he would have 2 years left at best, but decided to add him to clinical trials of Glivec for GIST patients. The whole treatment is paid for by our national health care, I believe it costs....$3000 per month, that's how much a single box of Glivec costs here and my dad has…
Re: Why Chemotherapy That Costs $70,000 in the U.S. Costs $2,500 in India
#17Chemotherapy is a form therapy where the medicine companies heal the the patient off his money and then kill him.
Re: Why Chemotherapy That Costs $70,000 in the U.S. Costs $2,500 in India
#18This is basically the paradox of US healthcare innovation. Canada can tell its pharmaceutical companies, "yeah, that cool drug you just invented, we're not gonna pay you what you want for that." And what option does the pharmaceutical company have? Convince healthcare providers to charge retail prices to their patients as an out-of-pocket expense, or... reduce prices accordingly. Because healthcare payments are not f…
That's a very misinformed statement.
Re: Why Chemotherapy That Costs $70,000 in the U.S. Costs $2,500 in India
#19Earlier quoted context omitted.
US firms are investing less in R&D relatively to their rank http://en.wikipedia.org/wiki/Pharmaceutical_industry#Market_... than their French/UK (publicly-funded healthcare) counterparts. The US are not "subsidizing it for poor countries" more than other rich countries. The truth in the case you're making is not specific to healthcare and is that "research (private and public) of rich countries that can afford it" be…
From that list 48.17% of all health care R&D spend is by US based companies. Sounds like the US is subsidizing the world to me.
Re: Why Chemotherapy That Costs $70,000 in the U.S. Costs $2,500 in India
#20Earlier quoted context omitted.
Actually, the problem in the US is in the lack of the balance between the producers and customers of medicine. In Canada, as you point out, there is a state monopoly on the purchasing side, but there is a similar monopoly on the selling side, in the form of medical patents. In India, there isn't a monopoly on either side. In the US, you have no monopoly on the healthcare side, but the drug companies have a monopoly o…
> In the US, you have no monopoly on the healthcare side, but the drug companies have a monopoly on the drugs they produce. In a way there is a monopoly on the healthcare side in the US, but it only impacts a certain segment of the population. Medicare is able to negotiate significant discounts on the cost of healthcare compared to private insurers precisely because for so many people it is the de facto provider. The…